Skip to main content
OpenTrials
Completed

NCT Number: NCT03943537

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and healthy controls.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

McLean Hospital

Belmont, Massachusetts, 02478, United States

About this study

Psychotic disorders are common and severe psychiatric disorders. Despite advances in understanding the pathophysiology of these disorders, more effective and tolerable treatments are still needed. Evidence suggests that energy metabolism is altered in psychotic disorders. The investigators recently developed non-invasive MRI-based techniques to quantify redox balance and ATP generation in the brain. Targeting insulin pathways in the brain may allow for modulating abnormalities in energy metabolism. The investigators seek to examine whether intranasal insulin can modulate energy metabolism and improve cognition in patients with psychotic disorders. The study will use magnetic resonance spectroscopy (MRS) technology to measure in vivo energy metabolism processes in the brain, before and after the administration of intranasal insulin. Investigators will also measure changes in cognition with the administration of intranasal insulin.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnoses of schizophrenia, schizoaffective disorder or bipolar disorder with psychotic features OR
  • Healthy Controls (no history of DSM psychiatric diagnoses, nor history of the same in first-degree relatives)

Exclusion criteria

  • Psychiatric hospitalization within the last 4 weeks
  • Unstable/active disease or potential contraindications, such as liver disease, kidney disease, uncontrolled hypertension, significant or unstable medical illness
  • Currently prescribed: antidiabetic agents, including oral antidiabetic medications and insulin, intranasal medication, steroids, weight loss agents
  • Pregnant or breast-feeding, not using an effective form of contraception for at least 3 months, and/or not abstinent for 1 month prior to enrollment
  • History of significant head injury
  • Contraindication to MRI scans (claustrophobia, cardiac pacemakers, metal clips and stents on blood vessels, artificial heart valves, artificial arms, hands, legs, etc., brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings, other metallic surgical hardware in vital areas, certain tattoos with metallic ink, certain transdermal patches, metal-containing IUDs).
  • Medical conditions preventing blood draws
  • History of electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the last 3 months
  • BMI > 35 or body weight > 350 lbs or BMI <18
  • DSM diagnosis of substance use disorder in the past month
  • For Healthy Controls:
  • Taking medication other than birth control

Treatment and study plan

Intranasal insulin

Drug

40 units Novolin R administered intranasally using ViaNase device.

Other names: Novolin R

Primary outcomes

  1. Changes in Brain Redox State

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in brain NAD+/NADH ratio as measured by in vivo 31P magnetic resonance spectroscopy

  2. Changes in Brain ATP

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in ATP concentration as measured by in vivo 31P magnetic resonance spectroscopy

  3. Changes in Brain PCr

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in Phosphocreatine (PCr) concentration as measured by in vivo 31P magnetic resonance spectroscopy

  4. Changes in Brain CK

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in creatine kinase (CK) enzyme rate as measured by in vivo 31P magnetic resonance spectroscopy

  5. Changes in STROOP Color-word Interference Score

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in STROOP assessment color-word condition interference score. This score is calculated as follows, with C being the number of items answered correctly in the color condition, W being the number answered correctly in the word condition, and CW being the number of items answered correctly in the color-word condition: CW - (C x W)/(C+W). Higher scores indicate better cognitive function.

  6. Changes in BACS Digit Sequencing Score

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in BACS digit sequencing scores, ranging from 0 - 36. Higher scores indicate better cognitive function.

  7. Changes in BACS Symbol Coding

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in BACS Symbol Coding test, with scores ranging from 0 - 110. Higher scores indicate better cognitive function.

  8. Changes in BACS Verbal Fluency Scores

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in BACS verbal fluency subscale z-scores, measured by number of words generated over 60-second trials. A z-score of 0 indicates the population mean. Higher scores indicate better cognitive function.

Secondary outcomes

  1. Changes in Brain pH.

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in pH as measured by in vivo 31P magnetic resonance spectroscopy

  2. Changes in Brain Inorganic Phosphate Concentration.

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in inorganic phosphate (Pi) concentration as measured by in vivo 31P magnetic resonance spectroscopy

  3. Change in Fasting Blood Glucose Levels.

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Safety outcome.

  4. Change in Fasting Blood Insulin Levels.

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Safety outcome.

  5. Change in Brain Glutamate Concentration

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in glutamate (Glu) concentration as measured by in vivo proton magnetic resonance spectroscopy

  6. Changes in Brain Glutamine Concentration

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in glutamine (Gln) concentration as measured by in vivo proton magnetic resonance spectroscopy

  7. Changes in Brain Glutathione Concentration

    Time frame: 6 hours, pre- and post- 40 IU intranasal insulin

    Changes in glutathione (GSH) concentration as measured by in vivo proton magnetic resonance spectroscopy

Sponsors and collaborators

Lead sponsor

Mclean Hospital

Other

Registry information

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
May 9, 2019
Registry last updated
Apr 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.